Daniel Morales Cano

Dr. Daniel Morales Cano

Centro Nacional de Investigaciones Cardiovasculares (CNIC)
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MCMaría Callejo
María Callejo
GMGema Mondejar-Parreño
Gema Mondejar-Parreño
BBBianca Barreira
Bianca Barreira
Jose L. Izquierdo-GarcíaJose L. Izquierdo-García
Jose L. Izquierdo-García
DCDaniel Morales Cano
Daniel Morales Cano
FPFrancisco Perez-Vizcaino
Francisco Perez-Vizcaino
We have analysed whether pulmonary arterial hypertension (PAH) alters the rat faecal microbiota. Wistar rats were injected with the VEGF receptor antagonist SU5416 (20 mg/kg s.c.) and followed for 2 weeks kept in hypoxia (10% O2, PAH) or injected with vehicle and kept in normoxia (controls). Faecal samples were obtained and microbiome composition was determined by 16S rRNA gene sequencing and bioinformatic analysis. No effect of PAH on the global microbiome was found (α- or β-diversity). However, PAH-exposed rats showed gut dysbiosis as indicated by a taxonomy-based analysis. Specifically, PAH rats had a three-fold increase in Firmicutes-to-Bacteroidetes ratio. Within the Firmicutes phylum, there were no large changes in the relative abundance of the bacterial families in PAH. Among Bacteroidetes, all families were less abundant in PAH. A clear separation was observed between the control and PAH clusters based on short chain fatty acid producing bacterial genera. Moreover, acetate was reduced in the serum of PAH rats. In conclusion, faecal microbiota composition is altered as a result of PAH. This misbalanced bacterial ecosystem might in turn play a pathophysiological role in PAH by altering the immunologic, hormonal and metabolic homeostasis.

2 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DCDaniel Morales Cano
Daniel Morales Cano
CMCarmen Menendez
Carmen Menendez
EMEnrique Moreno
Enrique Moreno
Javier Moral-SanzJavier Moral-Sanz
Javier Moral-Sanz
BBBianca Barreira
Bianca Barreira
FPFrancisco Perez-Vizcaino
Francisco Perez-Vizcaino
Quercetin is a dietary flavonoid which exerts vasodilator, antiplatelet and antiproliferative effects and reduces blood pressure, oxidative status and end-organ damage in humans and animal models of systemic hypertension. We hypothesized that oral quercetin treatment might be protective in a rat model of pulmonary arterial hypertension. Three weeks after injection of monocrotaline, quercetin (10 mg/kg/d per os) or vehicle was administered for 10 days to adult Wistar rats. Quercetin significantly reduced mortality. In surviving animals, quercetin decreased pulmonary arterial pressure, right ventricular hypertrophy and muscularization of small pulmonary arteries. Classic biomarkers of pulmonary arterial hypertension such as the downregulated expression of lung BMPR2, Kv1.5, Kv2.1, upregulated survivin, endothelial dysfunction and hyperresponsiveness to 5-HT were unaffected by quercetin. Quercetin significantly restored the decrease in Kv currents, the upregulation of 5-HT2A receptors and reduced the Akt and S6 phosphorylation. In vitro, quercetin induced pulmonary artery vasodilator effects, inhibited pulmonary artery smooth muscle cell proliferation and induced apoptosis. In conclusion, quercetin is partially protective in this rat model of PAH. It delayed mortality by lowering PAP, RVH and vascular remodeling. Quercetin exerted effective vasodilator effects in isolated PA, inhibited cell proliferation and induced apoptosis in PASMCs. These effects were associated with decreased 5-HT2A receptor expression and Akt and S6 phosphorylation and partially restored Kv currents. Therefore, quercetin could be useful in the treatment of PAH.

23 January 2015 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
DCDaniel Morales Cano
Daniel Morales Cano
LMLaura Moreno
Laura Moreno
BBBianca Barreira
Bianca Barreira
RPRachele Pandolfi
Rachele Pandolfi
VCVirginia Chamorro
Virginia Chamorro
ACAngel Cogolludo
Angel Cogolludo
Voltage-gated potassium channels encoded by KCNQ genes (Kv7 channels) are emerging as important regulators of vascular tone. In this study, we analysed the contribution of Kv7 channels to the vasodilation induced by hypoxia and the cyclic AMP pathway in the coronary circulation. We also assessed their regional distribution and possible impairment by diabetes. We examined the effects of Kv7 channel modulators on K+ currents and vascular reactivity in rat left and right coronary arteries (LCAs and RCAs, respectively). Currents from LCA were more sensitive to Kv7 channel inhibitors (XE991, linopirdine) and activators (flupirtine, retigabine) than those from RCA. Accordingly, LCAs were more sensitive than RCAs to the relaxation induced by Kv7 channel enhancers. Likewise, relaxation induced by the adenylyl cyclase activator forskolin and hypoxia, which were mediated through Kv7 channel activation, were greater in LCA than in RCA. KCNQ1 and KCNQ5 expression was markedly higher in LCA than in RCA. After incubation with high glucose (HG, 30 mmol/L), myocytes from LCA, but not from RCA, were more depolarized and showed reduced Kv7 currents. In HG-incubated LCA, the effects of Kv7 channel modulators and forskolin were diminished, and the expression of KCNQ1 and KCNQ5 was reduced. Finally, vascular responses induced by Kv7 channel modulators were impaired in LCA, but not in RCA, from type 1 diabetic rats. Our results reveal that the high expression and function of Kv7 channels in the LCA and their down-regulation by diabetes critically determine the sensitivity to key regulators of coronary tone.

1 November 2013 in Experimental and Toxicologic Pathology
Verified
Journal Article
Closed access
DCDaniel Morales Cano
Daniel Morales Cano
ECEva Calviño
Eva Calviño
VRVirginia Rubio
Virginia Rubio
AHAngel Herráez
Angel Herráez
PSPilar Sancho
Pilar Sancho
JDJosé C. Diez
José C. Diez

21 June 2018 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
GMGema Mondejar‐Parreño
Gema Mondejar‐Parreño
MCMaría Callejo
María Callejo
BBBianca Barreira
Bianca Barreira
DCDaniel Morales Cano
Daniel Morales Cano
SRSergio Antonio Esquivel Ruiz
Sergio Antonio Esquivel Ruiz
FPFrancisco Perez-Vizcaino
Francisco Perez-Vizcaino

27 July 2016 in Thorax
Verified
Journal Article
Open access
PDF file
RPRachele Pandolfi
Rachele Pandolfi
BBBianca Barreira
Bianca Barreira
EMEnrique Moreno
Enrique Moreno
VLVictor Lara-Acedo
Victor Lara-Acedo
DCDaniel Morales Cano
Daniel Morales Cano
LMLaura Moreno
Laura Moreno
Background Pulmonary hypertension (PH) is frequently observed in patients with acute respiratory distress syndrome (ARDS) and it is associated with an increased risk of mortality. Both acid sphingomyelinase (aSMase) activity and interleukin 6 (IL-6) levels are increased in patients with sepsis and correlate with worst outcomes, but their role in pulmonary vascular dysfunction pathogenesis has not yet been elucidated. Therefore, the aim of this study was to determine the potential contribution of aSMase and IL-6 in the pulmonary vascular dysfunction induced by lipopolysaccharide (LPS). Methods Rat or human pulmonary arteries (PAs) or their cultured smooth muscle cells (SMCs) were exposed to LPS, SMase or IL-6 in the absence or presence of a range of pharmacological inhibitors. The effects of aSMase inhibition in vivo with D609 on pulmonary arterial pressure and inflammation were assessed following intratracheal administration of LPS. Results LPS increased ceramide and IL-6 production in rat pulmonary artery smooth muscle cells (PASMCs) and inhibited pulmonary vasoconstriction induced by phenylephrine or hypoxia (HPV), induced endothelial dysfunction and potentiated the contractile responses to serotonin. Exogenous SMase and IL-6 mimicked the effects of LPS on endothelial dysfunction, HPV failure and hyperresponsiveness to serotonin in PA; whereas blockade of aSMase or IL-6 prevented LPS-induced effects. Finally, administration of the aSMase inhibitor D609 limited the development of endotoxin-induced PH and ventilation-perfusion mismatch. The protective effects of D609 were validated in isolated human PAs. Conclusions Our data indicate that aSMase and IL-6 are not simply biomarkers of poor outcomes but pathogenic mediators of pulmonary vascular dysfunction in ARDS secondary to Gram-negative infections.